
    
      OUTLINE: This is a multi-center study.

      21 Day Cycle Treatment Regimen:

        -  Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1

        -  ASA404 (given after Docetaxel) IV 1800 mg/m2 over approximately 20 minutes on Day 1

      Treatment will continue until disease progression or intolerable treatment related adverse
      effects.

      Karnofsky performance status of â‰¥ 70% within 7 days prior to registration for protocol
      therapy.

      Life Expectancy: Not specified

      Hematopoietic:

        -  Hemoglobin (Hgb) > 9 g/dL

        -  Platelets > 100 K/mm3

        -  Absolute neutrophil count (ANC) > 1.5 K/mm3

        -  INR or Prothrombin Time (PT) < 1.5 x ULN

      Hepatic:

        -  Bilirubin < 1.5 x ULN

        -  Aspartate aminotransferase (AST, ALT) < 2.5 x ULN

      Renal:

        -  Calculated creatinine clearance of > 45 cc/min using the Cockcroft-Gault formula

      Cardiovascular:

        -  No congestive heart failure (NY Heart Association class III or IV)

        -  No myocardial infarction within 12 months of study registration for protocol therapy or
           with implanted cardiac pacemaker

        -  No unstable or poorly controlled angina pectoris, including Prinzmetal variant angina
           pectoris
    
  